Telehealth & Digital Health

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

With millions of Canadians suffering from dry eye, a new program combines advanced tech like IPL with personalized plans to offer hope and accessible relief.

New research reveals a massive trust gap in healthcare AI as overall confidence drops. Why are users believers while the vast majority of Americans remain wary?

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

A new oral drug shows remarkable success in healing stubborn herpes lesions in people with HIV, offering a much-needed breakthrough for a vulnerable population.

Valant's AI Notes Assist now supports 100+ templates, aiming to reduce clinician burnout by fitting into existing workflows, not forcing new ones.

At Abarca Forward 2026, industry stakeholders and federal officials built a new playbook to transform the universally broken prior authorization process.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

A landmark partnership aims to bring precision cancer therapy, or Theranostics, to millions in underserved nations, backed by a major WHO resolution.

Japan becomes the first nation outside Israel to approve Alpha DaRT, a highly precise therapy for untreatable head and neck cancers. Here’s what it means.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

Verdiva Bio's VRB-101 aims to be the first once-weekly oral GLP-1, a potential game-changer for patients tired of daily pills and injections.

A landmark study confirms a minimally invasive radiofrequency device is highly effective for chronic rhinitis, offering lasting relief beyond traditional sprays.

With new backing from One Six 8 Ventures, health tech firm Respiree accelerates its US and Canadian expansion of its FDA-cleared AI platform.

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.